CreativeOne Wealth LLC Buys 5,730 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CreativeOne Wealth LLC grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 257.8% in the first quarter, HoldingsChannel reports. The fund owned 7,953 shares of the company’s stock after buying an additional 5,730 shares during the period. CreativeOne Wealth LLC’s holdings in Neurocrine Biosciences were worth $1,097,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Neurocrine Biosciences by 2.3% in the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after acquiring an additional 220,598 shares during the period. Brown Advisory Inc. raised its stake in Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after purchasing an additional 23,831 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Neurocrine Biosciences by 66.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares during the period. Vestal Point Capital LP bought a new stake in Neurocrine Biosciences during the fourth quarter worth about $105,408,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Neurocrine Biosciences by 10.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 686,835 shares of the company’s stock worth $90,497,000 after purchasing an additional 63,568 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded up $0.70 during trading hours on Friday, reaching $146.80. The company’s stock had a trading volume of 744,764 shares, compared to its average volume of 631,030. The firm has a fifty day simple moving average of $139.16 and a 200-day simple moving average of $137.90. The stock has a market cap of $14.77 billion, a P/E ratio of 40.44 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 52 week low of $99.36 and a 52 week high of $150.39.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The business had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 930 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total transaction of $139,527.90. Following the completion of the sale, the director now owns 119,047 shares of the company’s stock, valued at approximately $17,860,621.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the sale, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary A. Lyons sold 930 shares of Neurocrine Biosciences stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total transaction of $139,527.90. Following the completion of the sale, the director now directly owns 119,047 shares of the company’s stock, valued at approximately $17,860,621.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 80,709 shares of company stock valued at $11,009,150. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NBIX shares. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. Canaccord Genuity Group upped their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Citigroup upped their price objective on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Evercore ISI started coverage on shares of Neurocrine Biosciences in a research report on Tuesday, May 14th. They set an “outperform” rating and a $175.00 price objective for the company. Finally, HC Wainwright upped their price objective on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $154.08.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.